NCT03820180View on ClinicalTrials.gov

A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

January 23, 2019

Primary Completion Date

February 12, 2019

Study Completion Date

February 19, 2019

Conditions
Bioequivalence
Interventions
DRUG

Test Product

2 inhalations of Test and Reference product in each study period

DRUG

Reference Product

2 inhalations of Test and Reference product in each study period

Trial Locations (1)

41100

BECRO Clinical Facility, Larissa

All Listed Sponsors
collaborator

Becro Ltd.

INDUSTRY

lead

Respirent Pharmaceuticals Co Ltd.

INDUSTRY

NCT03820180 - A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers | Biotech Hunter | Biotech Hunter